VKH
ADAP

Virtu KCG Holdings’s Adaptimmune Therapeutics ADAP Stock Holding History

Virtu KCG Holdings’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$226K Buy
50,279
+26,105
+108% +$136K 0.01% 2030
2017
Q1 		$133K Buy
+24,174
New +$106K ﹤0.01% 2585
2015
Q3 		– Sell
-14,904
Closed -$273K – 3295
2015
Q2 		$273K Buy
+14,904
New +$256K ﹤0.01% 2190

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu KCG Holdings's ADAP Position: Q2 2017 in Review

Virtu KCG Holdings increased its Adaptimmune Therapeutics (ADAP) stake by 108% in Q2 2017, buying an estimated $136K and bringing the position to 50,279 shares worth $226K. The position accounts for 0.01% of the portfolio, ranked #2030.

Virtu KCG Holdings first reported a position in ADAP in Q2 2015 and has held it in 3 quarters since. The position peaked at $273K in Q2 2015. 56 funds tracked by Wall St. Rank hold ADAP as of Q2 2017.

  • Virtu KCG Holdings held 50,279 shares of Adaptimmune Therapeutics worth $226K as of Q2 2017.
  • Virtu KCG Holdings bought 26,105 Adaptimmune Therapeutics shares in Q2 2017, an estimated $136K.
  • Adaptimmune Therapeutics made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2030 holding.
  • Virtu KCG Holdings first reported a position in Adaptimmune Therapeutics in Q2 2015 and has held it in 3 quarters since.
  • Virtu KCG Holdings's Adaptimmune Therapeutics position peaked at $273K in Q2 2015.
  • 56 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.